Tue, Jul 22, 2014, 11:02 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Celgene Corp. (CELG) Message Board

mbren14340 9 posts  |  Last Activity: Jul 18, 2014 7:11 PM Member since: May 18, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Probability of Buyout vs. Offering

    by penguin_rescue Jul 15, 2014 9:36 PM
    mbren14340 mbren14340 Jul 18, 2014 7:11 PM Flag

    Frank...in your opinion, how long until this company starts making money?

  • mbren14340 by mbren14340 Jun 29, 2014 7:22 PM Flag

    After JJ resigned, the stock should have went down thinking he is the last to get off this sinking ship. Stock is not going down and seems to be headed even higher. I am finally starting to believe that JJ was forced to get out of the way so a deal could be done. Might add to my options position tomorrow morning depending on where the stock opens. Not expecting 20 a share like some people have posted. More like 5-6 a share in my opinion. Of course 20 would be nice. All just my opinion. Good luck to us longs.

  • mbren14340 mbren14340 Jun 18, 2014 4:28 PM Flag

    Sure hope your right. Thankfully I cut most of my loses awhile ago, but still holding some JAN15 calls. Good luck to us

  • mbren14340 mbren14340 Jun 18, 2014 3:55 PM Flag

    If this company was turning around or a deal was on the horizon, why did JJ resign?

  • Reply to


    by idnx50 Jun 14, 2014 6:16 PM
    mbren14340 mbren14340 Jun 14, 2014 7:26 PM Flag

    That's for sure.

  • mbren14340 by mbren14340 Jun 10, 2014 6:35 PM Flag

    Was optimistic about a buyout until yesterday when JJ announced his resignation. If there was any interest in this company at all, JJ would have left once the deal was done.

  • Reply to

    When will big pharma make a bid ?

    by westr May 30, 2014 3:40 PM
    mbren14340 mbren14340 May 30, 2014 7:21 PM Flag

    In my opinion, this should be a no brainer for many Big Pharma companies looking to add to their pipeline. A 50% premium or 24 dollars a share would value this company at about 630M. That's absolutely nothing for this company that can eventually do 400 million a year according to estimates.

  • Reply to

    probably worth a shot down here near $2

    by retailbaloon May 18, 2014 1:52 AM
    mbren14340 mbren14340 May 18, 2014 9:31 AM Flag

    I agree. No way that JJ and BOD are going to let this company go into bankruptcy. All has been very quiet for to long and that tells me that something is brewing. I find it hard to believe that there is no Big Pharma company interested in buying DNDN at a bargain price. Market Cap right now is at 325M. That's crazy for a company that has a cancer drug approved in US and EU. And yes, the drug extends life without all the horrible side effects and we still don't even know the true potential of Provenge when given earlier or in combination with other drugs. So why wouldn't Big Pharma take a shot? When you thing about it, DNDN is not that far from profitability on its own. Perhaps a year away or sooner depending on automation and EU sales. So if DNDN can get this to profitability on its own, can you image if Big Pharma takes over with a real sales force? All this said, if this company is acquired I really doubt it will be at a hefty premium that many on this board are dreaming about. Don't get me wrong, it sure would be nice, but just ain't happening in my opinion. I would guess buyout would be somewhere just south of 1 billion or around 5-6 a share. Taking into account the 600+ in debt less the cash on hand, Big Pharma would be paying about 1.4 billion. That's absolutely nothing for BIg Pharma who can turn this company around quick and possible get there money back in just a few years or less. This is all my opinion of course, but it wouldn't surprise me to hear some positive news sooner rather than later.

  • mbren14340 by mbren14340 May 4, 2014 10:15 AM Flag

    FDA approves before 5/28?

86.6576+1.3476(+1.58%)Jul 22 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.